


Acebilustat

Cat. No.:	HY-17625
CAS No.:	943764-99-6
Molecular Formula:	C ₂₉ H ₂₇ N ₃ O ₄
Molecular Weight:	481.54
Target:	Aminopeptidase
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 16.67 mg/mL (34.62 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		2.0767 mL	10.3834 mL	20.7667 mL
		5 mM		0.4153 mL	2.0767 mL	4.1533 mL
		10 mM		0.2077 mL	1.0383 mL	2.0767 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.67 mg/mL (3.47 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.67 mg/mL (3.47 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil					
	Solubility: ≥ 1.67 mg/mL (3.47 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory agent.
In Vitro	Acebilustat (CTX-4430) is a leukotriene A4 hydrolase inhibitor, which is safe and well tolerated in phase 1 trial ^[1] . Acebilustat is an antiinflammatory drug in development for the treatment of CF and other diseases. It is a potent inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), which catalyzes the rate-limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- bioRxiv. 2023 Oct 23.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Elborn JS, et al. Phase 1 Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. Clin Transl Sci. 2016 Nov 2
- [2]. Elborn JS, et al. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction. Clin Transl Sci. 2016 Oct 28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA